Join the Campaign

Walgreens study finds results from pharmacy, specialty clinic collaboration

Approximately 94% of hepatitis C patients who were prescribed direct-acting antiretrovirals (DAAs) were able to achieve the primary outcome goal, sustained virologic response (SVR), even though many patients had advanced liver disease, previous treatment failure, or previous liver transplants, according to a recent Walgreens Center for Health and W

Approximately 94% of hepatitis C patients who were prescribed direct-acting antiretrovirals (DAAs) were able to achieve the primary outcome goal, sustained virologic response (SVR), even though many patients had advanced liver disease, previous treatment failure, or previous liver transplants, according to a recent Walgreens Center for Health and Wellbeing Research study assessing a collaboration between Piedmont Healthcare's hepatitis C specialty clinic and a Walgreens local specialty pharmacy. "Collaboration between pharmacists and providers is key to optimizing patients’ response to treatment," said Shauna Markes-Wilson, study author and local specialty pharmacist for Walgreens. "Pharmacists provide high-touch support to overcome treatment challenges such as insurance prior-authorization and high copays. We ensure patient safety through drug interaction screening and patient education," she added. "We communicate regularly to ensure that patients are adherent to their care plans and address any side effects, while keeping our providers in the loop." The study, published in the Journal of the American Pharmacists Association, used a joint clinical and pharmacy database of patients who were prescribed DAAs. Outcomes assessed included time-to-therapy, SVR, insurance appeals, and copay assistance amount.

Ad Position: 
Bottom Center Aligned
Article URL: 
http://www.drugstorenews.com/article/walgreens-pharmacy-and-specialty-clinic-collaboration-drives-concrete-results
  • Join the Campaign
  • Take Action ALT Text
  • Get the facts ALT text
LATEST NEWS
October 17, 2017
October 17, 2017
APhA Executive Vice President and CEO Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA, testified in a hearing about drug prices held by the...
Gag clauses, lack of provider status hinder cost-effective care, importation is no solution, APhA CEO says
MORE
August 14, 2017
August 14, 2017
Tennessee saw major provider status legislation take effect on July 1. “Pharmacists as Providers” (HB 405/SB 461) gives Tennessee pharmacists formal...
‘Pharmacists as providers’ legislation went into effect July 1
MORE
July 13, 2017
July 13, 2017
The Massachusetts Senate and House of Representatives health care committee held a hearing on legislation that would expand the scope of practice...
Hearing held last month included testimony from pharmacists and physicians
MORE
Advertisement